A Study Analyzing Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients with SARS-Cov-2 During the Omicron Period
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 15 Mar 2023 New trial record
- 08 Mar 2023 Results published in the American Journal of Medicine